Infinity Pharmaceuticals Up 9%

Infinity Pharmaceuticals is up almost 9% after the company said it presented preclinical data for IPI-549, an oral immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma), that showed IPI-549 is able to help overcome resistance to checkpoint inhibition.

IPI-549 remodels the immune-suppressive tumor microenvironment primarily through its effects on myeloid cells, a type of cell considered to be involved in suppressing immune response against tumors.

Initial Phase 1 monotherapy data from nine patients with advanced solid tumors also showed the safety, pharmacokinetics and pharmacodynamics of IPI-549 monotherapy treatment appeared favorable.